


# potLight


## RealTime Dynamix™: Multiple Sclerosis Q2

This **Spherix Global Insights** report highlights responses from 101 neurologists about the evolving treatment patterns for disease-modifying therapies in MS. Emphasis on market shifts resulting from the introduction of Glatopa, the first generic DMT to enter the market, early indicators of likely uptake of Roche's Ocrevus including which DMTs face the greatest threat and where AbbVie/Biogen's Zinbryta will find its place in the treatment paradigm. This report offers a balance of trending metrics with fresh new content each quarter and helps clients stay up to date on this highly competitive and dynamic market.

Overall Change in DMT Use in Past Three Months




### Ocrelizumab...in ONE word



### New Information on Pipeline Agents


Neurologists have the greatest familiarity (and most excitement) with Roche's ocrelizumab




Percent of physicians reporting that this DMT is frequently or very frequently requested by patients



Neurologists report varying degrees of patient involvement when it comes to DMT brand selection and report that nearly 1 in 5 newly diagnosed patients do inquire about a specific brand




#### Degree of Patient Involvement in DMT brand selection



■ High  
■ Moderate  
■ Low

#### How Do You Choose?



- I choose (52%)
- I describe a few options and let the patient decide (31%)
- I describe ALL of the options and let the patient decide (10%)
- Other (7%)
- We check which ones are preferentially covered on insurance then decide (1%)